Atlas Trials

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

Clinical trial NCT04949113 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04949113
Sponsor
The Netherlands Cancer Institute
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Malignant Melanoma Stage III
Start date
2021-07-08
Primary completion
2024-01-12
Enrollment
423

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.